, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Improvement of survival with response to neoadjuvant radiation therapy for rectal cancer.

Castaldo ET, Parikh AA, Pinson CW, Feurer ID, Merchant NB
Arch Surg. 2009 144 (2): 129-34; discussion 134-5

PMID: 19221323 · DOI:10.1001/archsurg.2008.549

OBJECTIVES - To determine whether patients with a complete or near-complete response to neoadjuvant radiation therapy (XRT) have improved survival compared with those with less of a response and to compare survival between patients with disease downstaged after neoadjuvant XRT and patients with stage I disease undergoing resection alone.

DESIGN, SETTING, AND PATIENTS - Retrospective cohort of 10,971 patients (3760 patients with neoadjuvant XRT; 7211 with stage I disease with resection alone) from the Surveillance, Epidemiology, and End Results registry using data from January 1, 1994, through December 31, 2003.

MAIN OUTCOME MEASURES - Overall survival and disease-specific survival (DSS) of patients undergoing resection for nonmetastatic rectal adenocarcinoma receiving neoadjuvant XRT and patients with stage I disease undergoing surgical resection alone.

RESULTS - The 5-year DSS and overall survival were 94% and 82%, respectively, for responders to neoadjuvant XRT, 78% and 60%, respectively, for nonresponders, and 97% and 79%, respectively, for patients with stage I disease undergoing resection alone. Responders had improved DSS (P < .001) and overall survival (P < .001) compared with nonresponders by Cox regression. Patients with stage I disease undergoing resection alone had improved DSS (P = .01) but not overall survival (P = .89) compared with XRT responders.

CONCLUSIONS - Patients with rectal adenocarcinoma downstaged after neoadjuvant XRT have improved survival compared with nonresponders. While DSS is excellent for responders to neoadjuvant XRT, it did not equal the DSS of patients with stage I disease undergoing resection alone.

MeSH Terms (12)

Adenocarcinoma Aged Female Humans Kaplan-Meier Estimate Male Middle Aged Neoadjuvant Therapy Proportional Hazards Models Rectal Neoplasms SEER Program Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities:

Links